Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy changes since FDA's first biosimilar approval produce a label that is more clearly different than, but also more closely tied to, its brand reference.

Advertisement

Related Content

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register